A Phase 4 interventional study of Fluciclovine PET/CT in Prostate Cancer, sponsored by OHSU Knight Cancer Institute. Active, not recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by OHSU Knight Cancer Institute · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing fluciclovine F-18 in Prostatic Neoplasms — 2 open to participants now, 3 under way, none of them phase 3. fluciclovine F-18 · Prostatic Neoplasms.
Among the 14 studies testing fluciclovine F-18 in Prostatic Neoplasms, this one is the 5th largest by planned enrollment, is the only one that started in 2023, is one of 3 in phase 4, and was the 12th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →2 of the 14 studies testing fluciclovine F-18 in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Blue Earth Diagnostics · Sites in United States
Ages 18+ · Men only
Brigham and Women's Hospital · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
fluciclovine F-18: first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 2 · Phase 4 3
First in 2007; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 50 is below the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 28 across the 14 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
OHSU Knight Cancer Institute is the lead sponsor of 243 studies on the registry; 42 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 15 (56%) have results posted.
43 studies in Prostatic Neoplasms by OHSU Knight Cancer Institute: 4 open now, 7 under way, none of them phase 3. Of 31 finished, 14 (45%) have results posted.
Among the 43 studies in Prostatic Neoplasms by OHSU Knight Cancer Institute, this one is the 13th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 4, and was the 37th registered.
OHSU Knight Cancer Institute’s Prostatic Neoplasms studies by the year they started, since 1998.
2 of the studies testing fluciclovine F-18 in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05722925OHSU Knight Cancer InstituteEvaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET | 2026-12-01 |
| NCT06062745Brigham and Women's HospitalPilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing fluciclovine F-18 in Prostatic Neoplasms, from their registry updates:
Among OHSU Knight Cancer Institute’s 43 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this prospective cohort study is to investigate the role of Fluciclovine Positron Emission Tomography (PET) in patients with biochemical recurrence of prostate cancer (BCR) and a negative Prostate Specific Membrane Antigen (PSMA) PET, specifically, whether Fluciclovine PET can help detect local recurrence and whether the results of Fluciclovine PET can change management.
PRIMARY OBJECTIVE:
I. To evaluate the detection rate of local recurrence of prostate cancer on Fluciclovine PET in patients with BCR and a negative or equivocal PSMA PET obtained within 30 days prior to the Fluciclovine PET.
SECONDARY OBJECTIVES:
I. To evaluate the correct localization rate of Fluciclovine PET in patients with positive scans.
II. To distinguish the detection rate by site of recurrence (local recurrence in the prostate bed, lymph node involvement, or distant metastatic disease), and stratify by PSA level at the time of the scan and tumor grade
III. To evaluate the change in management based on the results of Fluciclovine PET, relative to intended management based on the result of negative PSMA PET alone, prior to obtaining the Fluciclovine PET.
OUTLINE:
Patients will be imaged with Fluciclovine PET within 30 days of the negative or equivocal PSMA scan.
A short questionnaire inquiring about the intended management will be sent to the referring physician at two timepoints: 1) the first is at the time of screening, prior to the Fluciclovine PET; and 2) the second is after the availability of the results of Fluciclovine PET.
Change in intended management will be recorded. Participants will be followed for 6 months and will be managed by their treating physician as per standard-of-care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo Fluciclovine PET/CT within 30 days of a negative or equivocal PSMA PET scan. After the Fluciclovine PET/CT, the patient will follow up with their treating physician as per standard-of-care. The research team will collect clinical and imaging data at 6 months post Fluciclovine-PET/CT.
Drug: Fluciclovine PET/CT
Drug page: Fluciclovine F-18Studies of Fluciclovine F-18Fluciclovine F-18 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
8 mCi (± 20%) of Fluciclovine administered as a bolus intravenous injection
Also known as: 18F-FACBC, Axumin®
Number of participants with BCR and a positive Fluciclovine PET performed within 30 days after a negative or equivocal PSMA PET
Time frame: During PET scan procedure
Correct localization rate (CLR) of Fluciclovine PET in patients with positive scans.
The CLR of Fluciclovine PET will be determined by the following formula: true positive/(true positive + false positive). This will be evaluated by patient, and only for patients in whom the standard-of-reference is available for analysis. Standard of reference, the combination of: 1. Pathology, if site of recurrence is biopsied 2. Drop in PSA levels if the site of recurrence undergoes radiation therapy 3. Imaging follow up confirming the suspicious finding as true positive.
Time frame: During PET scan procedure
Number of participants with positive Fluciclovine PET summarized by site of recurrence (local recurrence in the prostate bed, lymph node involvement, or distant metastatic disease), stratified by PSA level
Time frame: During PET scan procedure
Change in management based on the results of Fluciclovine PET, relative to intended management based on the result of negative PSMA PET alone, prior to obtaining the Fluciclovine PET.
Questionnaire filled by the referring physician stating the intended management at 2 timepoints, before and after the Fluciclovine PET/CT.
Time frame: Enrollment up to 1 month after scan
Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.
Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's planned 37 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluciclovine F-18
OHSU Knight Cancer Institute →